Abstract
High-fat diets and oxidative damage may contribute to the development of type 2 diabetes. Hypolipidaemic drugs and antioxidants were supposed to prevent the development of the disease. In this study, we investigated preventive effects of fenofibrate (200 mg kg(-1)), vitamin C (30 mg kg(-1)), combination of both in mice induced by streptozotocin (35 mg kg(-1)) and soluble lard (15 ml kg(-1)). The results showed the mice demonstrated hyperglycaemia and hypercholesterolaemia, visceral fat accumulation, and a slight increase in liver glycogen/triglyceride and oxidative stress within 60 days of treatment. Fenofibrate enhanced insulin sensitivity, improved glycaemic control, lowered serum triglycerides, reduced body and visceral fat weights, and decreased liver glycogen/lipid levels but showed hepatotoxicity in the mice. Vitamin C neither itself prevented nor enhanced preventive effects of fenofibrate on glucose and lipid metabolism but partly attenuated the hepatotoxicity of fenofibrate. These results suggest that fenofibrate inhibit development of type 2 diabetes induced by high-fat diets and oxidative stress. However, here, vitamin C just can serve as an adjunct to fenofibrate therapy against its hepatotoxicity. In the future study, we should investigate if higher dosage of vitamin C or other antioxidants would enhance preventive effects of fenofibrate in type 2 diabetes.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antioxidants / pharmacology
-
Ascorbic Acid / pharmacology
-
Blood Glucose / drug effects
-
Chemical and Drug Induced Liver Injury
-
Cholesterol / blood
-
Diabetes Mellitus, Experimental / chemically induced
-
Diabetes Mellitus, Experimental / metabolism
-
Diabetes Mellitus, Experimental / physiopathology
-
Diabetes Mellitus, Experimental / prevention & control*
-
Diabetes Mellitus, Type 2 / chemically induced
-
Diabetes Mellitus, Type 2 / metabolism
-
Diabetes Mellitus, Type 2 / physiopathology
-
Diabetes Mellitus, Type 2 / prevention & control*
-
Dietary Fats
-
Drug Therapy, Combination
-
Fenofibrate / pharmacology*
-
Fenofibrate / therapeutic use
-
Fenofibrate / toxicity
-
Glycogen / metabolism
-
Hypercholesterolemia / chemically induced
-
Hypercholesterolemia / metabolism
-
Hypercholesterolemia / prevention & control
-
Hyperglycemia / chemically induced
-
Hyperglycemia / metabolism
-
Hyperglycemia / physiopathology
-
Hyperglycemia / prevention & control*
-
Hypoglycemic Agents / pharmacology*
-
Hypoglycemic Agents / therapeutic use
-
Hypoglycemic Agents / toxicity
-
Hypolipidemic Agents / pharmacology*
-
Hypolipidemic Agents / therapeutic use
-
Hypolipidemic Agents / toxicity
-
Insulin Resistance*
-
Intra-Abdominal Fat / drug effects*
-
Intra-Abdominal Fat / metabolism
-
Liver / drug effects
-
Liver / metabolism
-
Liver Diseases / metabolism
-
Male
-
Matrix Metalloproteinase 9 / metabolism
-
Mice
-
Oxidative Stress / drug effects
-
Streptozocin
-
Triglycerides / blood
-
Triglycerides / metabolism
Substances
-
Antioxidants
-
Blood Glucose
-
Dietary Fats
-
Hypoglycemic Agents
-
Hypolipidemic Agents
-
Triglycerides
-
Streptozocin
-
Glycogen
-
Cholesterol
-
Matrix Metalloproteinase 9
-
Ascorbic Acid
-
lard
-
Fenofibrate